BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37248740)

  • 21. Successful treatment of myeloid neoplasms associated with PDGFRA rearrangement with imatinib mesylate.
    Sun CY; Hu Y; Chu ZB; Guo T; He J
    Int J Hematol; 2009 Jan; 89(1):66-70. PubMed ID: 19096755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
    Gotlib J; Cools J; Malone JM; Schrier SL; Gilliland DG; Coutré SE
    Blood; 2004 Apr; 103(8):2879-91. PubMed ID: 15070659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
    Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P
    Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement.
    Williams C; Kalra S; Nath U; Bown N; Wilson V; Wilkins BS; Neylon AJ
    J Clin Pathol; 2008 May; 61(5):677-80. PubMed ID: 18256119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.
    Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G
    Haematologica; 2007 Sep; 92(9):1173-9. PubMed ID: 17666373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.
    Barraco D; Carobolante F; Candoni A; Simeone E; Piccaluga P; Tabanelli V; Fanin R
    Eur J Haematol; 2014 Jun; 92(6):541-5. PubMed ID: 24460680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
    Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J
    Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy].
    Sekkach Y; Mekouar F; Jira M; Elqatni M; Elomri N; Fatihi J; Badaoui M; Hammi S; Smaali J; El Khattabi A; Amezyane T; Abouzahir A; Ghafir D
    Ann Pharm Fr; 2011 Sep; 69(5):277-81. PubMed ID: 21924129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.
    Arai A; Yan W; Wakabayashi S; Hayashi S; Inazawa J; Miura O
    Int J Hematol; 2007 Oct; 86(3):233-7. PubMed ID: 17988989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].
    Menif S; Ben Romdhane N; Hafsia R
    Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
    Helbig G; Kyrcz-Krzemień S
    Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
    [No Abstract]   [Full Text] [Related]  

  • 32. A case of myeloid neoplasm with FIP1L1-PDGFRA rearrangement without marked peripheral blood eosinophilia.
    Wang J; Zhang Q; Zeng H; Chen B; Ouyang J
    Pharmacogenomics; 2016; 17(2):99-102. PubMed ID: 26666578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.
    Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Seferyńska I; Hałasz M; Woszczyk D; Markiewicz M; Krzemień S
    Hematol Oncol; 2010 Jun; 28(2):93-7. PubMed ID: 19728396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generalized Eruptive Histiocytosis Associated With FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia.
    Ziegler B; Peitsch WK; Reiter A; Marx A; Goerdt S; Géraud C
    JAMA Dermatol; 2015 Jul; 151(7):766-9. PubMed ID: 25923837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome].
    Martinaud C; Souraud JB; Cournac JM; Pons S; Ménard G; de Jaureguiberry JP; Brisou P
    Rev Med Interne; 2011 May; 32(5):e66-8. PubMed ID: 20633965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficiency of imatinib in polyserositis revealing a FIP1L1-PDGFRA-negative hypereosinophilic syndrome].
    Green L; Kahn JE; Dufour JF; Le Scanff J; Charhon A; Broussolle C; Sève P
    Rev Med Interne; 2010 Apr; 31(4):305-8. PubMed ID: 20167399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
    Li B; Zhang GS; Dai CW; Pei MF
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia.
    Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE
    Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057
    [No Abstract]   [Full Text] [Related]  

  • 39. Idiopathic hypereosinophilic syndrome in children: report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement.
    Rives S; Alcorta I; Toll T; Tuset E; Estella J; Cross NC
    J Pediatr Hematol Oncol; 2005 Dec; 27(12):663-5. PubMed ID: 16344672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia.
    Tanaka H; Iwato K; Asou H; Kimura A
    Intern Med; 2010; 49(12):1195-200. PubMed ID: 20558942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.